ArticleCardiovascular diabetology2021

The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin.

Vincenzo Quagliariello et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.